Drug significantly increases risk of death, stroke

[Guest guest]

http://www.msnbc.msn.com/id/4327542/

 

Zyprexa maker issues warning for elderly

Drug significantly increases risk of death, stroke

 

Updated: 2:30 p.m. ET Feb. 20, 2004

 

 

NEW YORK - Eli Lilly and Co. on Friday said it has warned doctors that its

schizophrenia treatment Zyprexa, its best-selling drug, significantly raises the

risk of death and stroke in elderly patients suffering from dementia.

 

 

The Indianapolis-based company said it sent a letter to U.S. doctors on Jan. 15

warning that Zyprexa, which had global sales of $4.3 billion in 2003 and

accounts for half of Lilly’s profit, increased the risks in five clinical trials

among elderly patients with dementia.

 

“I don’t think we have a sense of why,” said Lilly spokesman Dan Collins. Higher

stroke and death risks have not been seen in other populations, he said.

 

Similarly, Johnson & Johnson last April warned U.S. doctors that its own

schizophrenia drug, Risperdal, raises the risk of stroke among elderly patients

with dementia.

 

Drugs widely used in treating dementia patients

Zyprexa and Risperdal, J & J’s second-biggest drug with 2003 sales of $2.5

billion, are widely used to control behavioral disorders among dementia

patients, such as delusions, aggression and anxiety.

 

Lilly’s warning letter said 3.5 percent of elderly patients with dementia taking

Zyprexa in the trials died of all causes, more than twice the death rate of 1.5

percent seen among those taking placebos.

 

Public Citizen, a consumer watchdog group, has criticized doctors for routinely

prescribing schizophrenia drugs to treat symptoms of dementia, including

Alzheimer’s disease, even though the medicines are not approved for that use.

 

Doctors may legally prescribe drugs for uses not approved by the U.S. Food and

Drug Administration, although drugmakers are allowed to market their products

only for specifically approved uses.

 

Some doctors have defended such “off-label” use of schizophrenia drugs, saying

it would be hard for many dementia patients to live at home without them and

that the increased risk of stroke must be balanced against the higher quality of

life the medicines may provide.

 

Collins said Lilly could not advise doctors whether to prescribe Zyprexa for

dementia because it is not officially approved for that use by U.S. regulators.

 

“It is the professional judgment of doctors how they monitor medicines,” said

Collins. He said about 2 percent of Zyprexa sales are for elderly patients with

dementia.

Copyright 2004 Reuters Limited. All rights reserved. Republication or

redistribution of Reuters content is expressly prohibited without the prior

written consent of Reuters.

 

 

 

 

 

 

Mail SpamGuard - Read only the mail you want.